Products
Semzuvolimab Biosimilar Monoclonal Antibody (CD4) for Research
Cat No.: GMP-Bios-INN-1383
Anti-CD4 therapeutic antibody (Pre-made Semzuvolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Semzuvolimab (development code UB-421) is a humanized monoclonal antibody targeting CD4. It is developed by United Biopharma and Kaohsiung Medical University Chung-Ho Memorial Hospital and Kaohsiung Veterans General Hospital and United Biomedical for HIV1 infections in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1383-1mg | 1mg | 3090 |
| GMP-Bios-INN-1383-10mg | 10mg | |
| GMP-Bios-INN-1383-100mg | 100mg | |
| GMP-Bios-INN-1383-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Semzuvolimab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-CD4/T-cell surface glycoprotein CD4/T-cell surface antigen T4/Leu-3 therapeutic antibody |
| INN Name | Semzuvolimab |
| Target | CD4 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | United Biopharma;Kaohsiung Medical University Chung-Ho Memorial Hospital;Kaohsiung Veterans General Hospital;United Biomedical |
| Conditions Approved | na |
| Conditions Active | HIV1 infections |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
